3.62

2.43% -0.09

After Hours: 3.60 -0.02 -0.55%

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $3.62, with a volume of 456.42K. It is down -2.43% in the last 24 hours and up +11.73% over the past month. 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Previous Close:

$3.71

Open:

$3.68

24h Volume:

456.42K

Relative Volume:

0.73

Market Cap:

$167.71M

Revenue:

$20.72M

Net Income/Loss:

$-100.84M

P/E Ratio:

-1.3609

EPS:

-2.66

Net Cash Flow:

$-78.56M

1W Performance:

+3.72%

1M Performance:

+11.73%

6M Performance:

-53.83%

1Y Performance:

-85.31%

1-Day Range:

$3.48

$3.72

1-Week Range:

$3.365

$3.805

52-Week Range:

$2.235

$28.93

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

227

Twitter

Next Earnings Date

2024-12-13

Latest SEC Filings

FDMT's Discussions on Twitter

Compare FDMT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FDMT 4 D Molecular Therapeutics Inc	3.62	161.67M	20.72M	-100.84M	-78.56M	-2.66
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Nov-21-24	Initiated	Morgan Stanley	Underweight
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

04:27 AM

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

04:27 AM

May 29, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Lowered by D. E. Shaw & Co. Inc. - Defense World

May 29, 2025

May 28, 2025

4DMT to Participate in Upcoming Investor Conferences | FDMT Stock News - GuruFocus

May 28, 2025

4DMT to Participate in Upcoming Investor Conferences - Eagle-Tribune

May 28, 2025

4DMT Leadership to Present Latest Biotech Advances at Two Major Healthcare Conferences in June - Stock Titan

May 28, 2025

May 27, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Receives Sell (E+) Rating from Weiss Ratings - Defense World

May 27, 2025

Millennium Management LLC Acquires 1,337,497 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 27, 2025

May 26, 2025

4D Molecular Therapeutics’ SWOT analysis: gene therapy stock faces durability challenges amid pipeline progress - Investing.com

May 26, 2025

May 25, 2025

Deutsche Bank AG Sells 560,784 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 25, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Acquired by Northern Trust Corp - Defense World

May 25, 2025

BNP Paribas Financial Markets Makes New Investment in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 25, 2025

May 21, 2025

Spotlight On 3 Penny Stocks With Market Caps Under $500M - Yahoo Finance

May 21, 2025

Jane Street Group LLC Increases Stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 21, 2025

May 18, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World

May 18, 2025

May 17, 2025

Dimensional Fund Advisors LP Cuts Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 17, 2025

May 16, 2025

4DMT Boosts Talent Acquisition: 31,800 RSUs Granted as Biotech Firm Accelerates Growth - Stock Titan

May 16, 2025

May 15, 2025

FY2025 EPS Estimates for FDMT Decreased by Cantor Fitzgerald - Defense World

May 15, 2025

HC Wainwright Analysts Boost Earnings Estimates for FDMT - Defense World

May 15, 2025

May 12, 2025

Chardan Adjusts Price Target on 4D Molecular Therapeutics to $25 From $28, Maintains Buy Rating - marketscreener.com

May 12, 2025

Hsbc Holdings PLC Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

May 12, 2025

Barclays Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $38.00 - Defense World

May 12, 2025

The Goldman Sachs Group Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $44.00 - Defense World

May 12, 2025

Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $25.00 - Defense World

May 12, 2025

May 11, 2025